﻿               SEQUENCE LISTING

<110> Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.

<120> Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien

<130> FH59577PC

<150>  EP102018213030.2
<151>  2018-08-3

<160> 4

<170> BiSSAP 1.3.6

<210> 1
<211> 591
<212> PRT
<213> Candidatus Savagella


<220> 
<223> Myosin-cross-reactive antigen

<400> 1
Met Tyr Tyr Ser Ser Gly Asn Tyr Glu Ala Phe Ala Arg Pro Ile Lys 
1               5                   10                  15      
Pro Glu Gly Val Asp Asn Lys Ser Ala Tyr Leu Ile Gly Ser Gly Leu 
            20                  25                  30          
Ala Ser Leu Val Ala Ala Phe Tyr Leu Val Arg Asp Ala Gln Met Lys 
        35                  40                  45              
Gly Glu Asn Ile His Ile Leu Glu Lys Asp Ser Ile Pro Gly Gly Ala 
    50                  55                  60                  
Cys Asp Gly Phe Asp Tyr Lys Gly Ile Gly Tyr Val Met Arg Gly Gly 
65                  70                  75                  80  
Arg Glu Ile Asp Asn His Tyr Glu Ile Leu Trp Asp Val Phe Arg Ser 
                85                  90                  95      
Val Pro Ser Ile Glu Ile Glu Gly Ala Ser Val Leu Asp Glu Phe Tyr 
            100                 105                 110         
Trp Leu Asp Lys Lys Asp Pro Asn Tyr Ser Leu Arg Arg Ala Thr Val 
        115                 120                 125             
Asn Arg Gly Glu Asp Ala Lys Met Glu Asn Lys Phe Gly Leu Ser Asp 
    130                 135                 140                 
Lys Ala Ser Leu Gln Ile Met Arg Leu Phe Phe Thr Pro Asp Glu Asp 
145                 150                 155                 160 
Leu Tyr Asp Lys Pro Ile Thr Asp Tyr Phe Asp Asp Glu Val Leu Lys 
                165                 170                 175     
Ser Asn Phe Trp Leu Tyr Trp Arg Thr Met Phe Ala Phe Gln Asn Trp 
            180                 185                 190         
His Ser Ala Leu Glu Met Lys Leu Tyr Ile Lys Arg Phe Ile His His 
        195                 200                 205             
Ile Gly Gly Met Pro Asp Phe Lys Ala Val Arg Phe Thr Arg Arg Asn 
    210                 215                 220                 
Gln Tyr Glu Ser Met Ile Leu Pro Leu Ile Lys Tyr Leu Glu Ser His 
225                 230                 235                 240 
Asn Val Asp Phe Gln Tyr Asn Thr Lys Val Val Asp Val Glu Phe Asp 
                245                 250                 255     
Ile Gln Pro His Lys Lys Gln Ala Thr Ser Ile Lys Ile Leu Arg Asp 
            260                 265                 270         
Gly Lys Glu Glu Glu Ile Lys Leu Thr Glu Asn Asp Leu Leu Phe Ile 
        275                 280                 285             
Thr Asn Gly Gly Cys Val Glu Asn Ser Ser Ile Gly Ser Gln Asn Thr 
    290                 295                 300                 
Pro Ala Val Leu Asn Ser Glu Ile Lys Glu Gly Gly Gly Trp Asp Met 
305                 310                 315                 320 
Trp Arg Arg Ile Ser Val Lys Asp Pro Ser Phe Gly Asn Pro Asp Lys 
                325                 330                 335     
Phe Cys Tyr Asp Ala Glu Lys Ser Asn Trp Met Ser Ala Thr Val Thr 
            340                 345                 350         
Val Leu Asp Asp Lys Ile Val Pro Tyr Ile Lys Asn Ile Cys Gln Arg 
        355                 360                 365             
Asp Pro Phe Ser Gly Lys Val Val Thr Gly Gly Ile Val Thr Val Lys 
    370                 375                 380                 
Asp Ser Lys Trp Leu Leu Ser Trp Thr Phe Asn Arg Gln Pro Gln Phe 
385                 390                 395                 400 
Arg Glu Gln Pro Lys Gly Gln Leu Val Gly Trp Ile Tyr Gly Leu Phe 
                405                 410                 415     
Ser Asp Val Ala Gly Asp Tyr Ile Lys Lys Pro Met Arg Asp Cys Thr 
            420                 425                 430         
Gly Lys Glu Ile Cys Met Glu Trp Leu Tyr His Leu Gly Val Pro Glu 
        435                 440                 445             
Asp Gln Ile Val Asp Leu Ala Glu Asn His Ala Asn Thr Val Pro Cys 
    450                 455                 460                 
Met Met Pro Tyr Ile Thr Ala Phe Phe Met Pro Arg Ser Lys Gly Asp 
465                 470                 475                 480 
Arg Pro Asn Val Val Pro Thr Gly Ser Val Asn Phe Ala Phe Ile Gly 
                485                 490                 495     
Gln Phe Ala Glu Thr Glu Arg Asp Thr Ile Phe Thr Ile Glu Tyr Ser 
            500                 505                 510         
Ala Arg Thr Gly Ile Glu Ser Val Tyr Thr Leu Leu Asn Val Asp Arg 
        515                 520                 525             
Gly Val Pro Glu Val Trp Gly Ser Thr Phe Asp Ile Arg Asp Leu Val 
    530                 535                 540                 
Asn Ala Thr Tyr Cys Met Arg Asp Gly Lys Lys Ile Thr Asp Met Lys 
545                 550                 555                 560 
Leu Gly Phe Lys Glu Asn Ile Ala Leu Lys Glu Leu Leu Lys Lys Ile 
                565                 570                 575     
Ser Gly Thr Asp Val Glu Lys Leu Leu Lys Glu Tyr Lys Leu Ile 
            580                 585                 590     

<210> 2
<211> 17
<212> PRT
<213> Artificial Sequence


<220> 
<223> Target 1

<400> 2
Ser Val Leu Asp Glu Phe Tyr Trp Leu Asp Lys Lys Asp Pro Tyr Ser 
1               5                   10                  15      
Leu 
    

<210> 3
<211> 18
<212> PRT
<213> Artificial Sequence


<220> 
<223> Target 2

<400> 3
Pro Asp Phe Lys Ala Val Arg Phe Thr Arg Arg Asn Gln Tyr Glu Ser 
1               5                   10                  15      
Met Ile 
        

<210> 4
<211> 18
<212> PRT
<213> Artificial Sequence


<220> 
<223> Target 3

<400> 4
Gln Ala Thr Ser Ile Lys Ile Leu Arg Asp Gly Lys Glu Glu Glu Ile 
1               5                   10                  15      
Lys Leu 
        

